医学
体质指数
人口学
1型糖尿病
糖尿病
比例危险模型
2型糖尿病
2型糖尿病
内科学
老年学
内分泌学
社会学
作者
Alexandria Ratzki‐Leewing,Jason Black,Bridget L. Ryan,Guangyong Zou,Neil Klar,Susan Webster-Bogaert,Kristina Timcevska,Stewart B. Harris
摘要
Abstract Aims We aimed to develop and internally validate a real‐world prognostic model for Level 3 hypoglycaemia risk compatible with outpatient care in the United States. Materials and Methods iNPHORM is a 12‐month, US‐based panel survey. Adults (18‐90 years old) with type 1 diabetes mellitus or insulin‐ and/or secretagogue‐treated type 2 diabetes mellitus were recruited from a nationwide, probability‐based internet panel. Among participants completing 1 follow‐up questionnaire(s), we modelled 1‐year Level 3 hypoglycaemia risk using Andersen and Gill's Cox survival and penalized regression with multiple imputation. Candidate variables were selected for their clinical relevance and ease of capture at point‐of‐care. Results In total, 986 participants [type 1 diabetes mellitus: 17%; men: 49.6%; mean age: 51 (SD: 14.3) years] were analysed. Across follow‐up, 035.1 (95% CI: 32.2‐38.1)% reported ≥1 Level 3 event(s), and the rate was 5.0 (95% CI: 4.1‐6.0) events per person‐year. Our final model showed strong discriminative validity and parsimony (optimism corrected c‐statistic: 0.77). Numerous variables were selected: age; sex; body mass index; marital status; level of education; insurance coverage; race; ethnicity; food insecurity; diabetes type; glycated haemoglobin value; glycated haemoglobin variability; number, type and dose of various medications; number of SH events requiring hospital care (past year and over follow‐up); type and number of comorbidities and complications; number of diabetes‐related health care visits (past year); use of continuous/flash glucose monitoring; and general health status. Conclusions iNPHORM is the first US‐based primary prognostic study on Level 3 hypoglycaemia. Future model implementation could potentiate risk‐tailored strategies that reduce real‐world event occurrence and overall diabetes burden.
科研通智能强力驱动
Strongly Powered by AbleSci AI